Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Belatacept (Primary) ; Antithymocyte globulin; Rituximab
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 20 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2015 Planned End Date changed from 1 Jun 2021 to 1 Aug 2021, as reported by ClinicalTrials.gov.
- 01 Dec 2015 Planned primary completion date changed from 1 Dec 2020 to 1 Mar 2021, as reported by ClinicalTrials.gov.